SHELTON, Conn., Jan. 12, 2016 /PRNewswire/ -- NanoViricides,
Inc. (NYSE MKT: NNVC) (the "Company"), a nanomedicine company
developing anti-viral drugs, reported that its CEO, Eugene Seymour, MD, MPH, will be speaking at the
Biotech Showcase conference in San
Francisco at 9 am PST Wednesday
January 13, 2016. The Biotech Showcase conference is being
held at the Parc 55 Hotel in San
Francisco, California, from January
11 to January 13th, 2016.
His talk, along with his slides, will be webcast. The link to
the webcast is https://edge.media-server.com/m/p/kjpfohi2
Dr Seymour will discuss the progress the Company has made since
the prior Biotech Showcase conference held a year ago. He will
discuss the Company's strategic focus on the HerpeCide™ program,
including drug development for herpes keratitis, a potentially
blinding disease of the eye. The Company believes that it has
achieved the production scale necessary to supply sufficient
quantities of an anti-herpes drug candidate for all of the IND
enabling studies as well as forthcoming human clinical trials after
filing an IND.
NanoViricides's management will host one-on-one meetings with
conference attendees at Biotech Showcase 2016. These meetings have
been scheduled through the conference's partnering360 system.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage
company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-ceo-dr-eugene-seymour-to-present-at-the-biotech-showcase-in-san-francisco-on-wednesday-300202881.html
SOURCE NanoViricides, Inc.